Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53451
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCops, E.en
dc.contributor.authorBianco-Miotto, T.en
dc.contributor.authorMoore, N.en
dc.contributor.authorClarke, C.en
dc.contributor.authorBirrell, S.en
dc.contributor.authorButler, L.en
dc.contributor.authorTilley, W.en
dc.date.issued2008en
dc.identifier.citationJournal of Steroid Biochemistry and Molecular Biology, 2008; 110(3-5):236-243en
dc.identifier.issn0960-0760en
dc.identifier.issn1879-1220en
dc.identifier.urihttp://hdl.handle.net/2440/53451-
dc.descriptionCopyright © 2008 Elsevier Ltd All rights reserved.en
dc.description.abstractAndrogen signaling, mediated by the androgen receptor (AR), is a critical factor influencing growth of normal and malignant breast cells. Given the increasing use of exogenous androgens in women, a better understanding of androgen action in the breast is essential. This study compared the effects of 5alpha-dihydrotestosterone (DHT) and a synthetic androgen, mibolerone, on estradiol (E(2))-induced proliferation of breast cancer cells. DHT modestly inhibited E(2)-induced proliferation and mibolerone significantly inhibited proliferation in T-47D cells. The effects of both androgens could be reversed by an AR antagonist, suggesting that their actions were mediated, in part, by AR. Whereas high physiological doses (10-100nM) of DHT reduced E(2)-mediated induction of the estrogen-regulated gene progesterone receptor (PR) to basal levels, mibolerone at lower doses (1nM) eliminated PR expression, suggesting that mibolerone may also act via the PR. In the AR positive, PR-negative MCF-7 cells, mibolerone had modest effects on E(2)-induced proliferation, but was a potent inhibitor of proliferation in the AR positive, PR positive MCF-7M11 PRA cells. The effects of mibolerone in breast cancer cells were similar to those of the progestin, medroxyprogesterone acetate. Our results demonstrate that mibolerone can have both androgenic and progestagenic actions in breast cancer cells.en
dc.description.statementofresponsibilityElisa J. Cops, Tina Bianco-Miotto, Nicole L. Moore, Christine L. Clarke, Stephen N. Birrell, Lisa M. Butler and Wayne D. Tilleyen
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/333/description#descriptionen
dc.language.isoenen
dc.publisherPergamon-Elsevier Science Ltden
dc.subjectTumor Cells, Cultured; Humans; Breast Neoplasms; Dihydrotestosterone; Estradiol; Nandrolone; Testosterone Congeners; Receptors, Androgen; Receptors, Progesterone; Androgens; Progestins; Drug Evaluation, Preclinical; Cell Proliferation; Medroxyprogesterone Acetateen
dc.titleAntiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptorsen
dc.typeJournal articleen
dc.identifier.rmid0020081525en
dc.identifier.doi10.1016/j.jsbmb.2007.10.014en
dc.identifier.pubid42743-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidBianco-Miotto, T. [0000-0002-8431-5338]en
dc.identifier.orcidButler, L. [0000-0003-2698-3220]en
dc.identifier.orcidTilley, W. [0000-0003-1893-2626]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.